RESUMO
The etiology of feline hyperesthesia syndrome can be difficult to determine. Behavior modification and medications may help in treatment.
Assuntos
Comportamento Animal , Doenças do Gato/diagnóstico , Hiperestesia/veterinária , Animais , Antidepressivos Tricíclicos/uso terapêutico , Benzodiazepinas/uso terapêutico , Doenças do Gato/terapia , Gatos , Diagnóstico Diferencial , Hiperestesia/diagnóstico , Hiperestesia/terapia , Prognóstico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , SíndromeRESUMO
Canine separation anxiety is a common behavioral problem presented to veterinarians. Associated behaviors are distressing to both dog and owner, have the potential to disrupt the human-companion animal bond, and may lead to euthanasia. The results of this study demonstrate the clinical efficacy and safety of Reconcile (fluoxetine, 1 to 2 mg/kg/day [0.45 to 0.91 mg/lb/day]), in conjunction with behavior management, for the treatment of canine separation anxiety. The beef flavored chewable formulation was palatable to treated dogs and easy to administer. This study provides to veterinarians and owners valuable information about an effective separation anxiety treatment plan that combines use of Reconcile with behavior modification.
Assuntos
Antidepressivos de Segunda Geração/administração & dosagem , Ansiedade de Separação/tratamento farmacológico , Comportamento Animal , Doenças do Cão/tratamento farmacológico , Fluoxetina/administração & dosagem , Inibidores Seletivos de Recaptação de Serotonina/administração & dosagem , Administração Oral , Animais , Ansiedade de Separação/psicologia , Canadá , Doenças do Cão/psicologia , Cães , Método Duplo-Cego , Vínculo Humano-Animal , Humanos , Resultado do Tratamento , Estados UnidosRESUMO
OBJECTIVE: To determine bioavailability, pharmacokinetics, and safety for transdermal (TD) and oral administration of fluoxetine hydrochloride to healthy cats. ANIMALS: 12 healthy mixed-breed sexually intact 1- to 4-year-old purpose-bred cats. PROCEDURE: A single-dose pharmacokinetic study involving 3 groups of 4 cats each was conducted in parallel. Fluoxetine in a formulation of pluronic lecithin organogel (PLO gel) was applied to the hairless portion of the pinnae of cats at 2 dosages (5 or 10 mg/kg), or it was administered orally in capsules at a dosage of 1 mg/kg. Plasma samples were obtained and submitted for liquid chromatography-mass spectrometry-mass spectrometry analysis of fluoxetine and its active metabolite, norfluoxetine. RESULTS: Peak fluoxetine concentration (Cmax) was lower and time to Cmax longer for TD administration versus oral administration. Relative bioavailability of each dose administered via the TD route was 10% of the value for oral administration of the drug. Mean plasma elimination half-life after oral administration was 47 and 55 hours for fluoxetine and norfluoxetine, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: This study provides evidence that fluoxetine in a 15% (wt:vol) PLO gel formulation can be absorbed through the skin of cats into the systemic circulation. However, the relative bioavailability for TD administration is approximately only 10% of that for the oral route of administration.